Evidence map›Paper›PMID 26009004›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2015

D-Galactosamine Intoxication in Experimental Animals: Is it Only an Experimental Model of Acute Liver Failure?

Marek Saracyn, Robert Zdanowski, Marek Brytan, Grzegorz Kade, Zbigniew Nowak, Janusz Patera, Przemysław Dyrla, Jerzy Gil, Zofia Wańkowicz

Open access · hybridAbstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Recent developments inDrug metabolism reviews · 2021
    Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Marek SaracynDepartment of Internal Diseases, Nephrology and Dialysis, Military Institute of Medicine, Warsaw, Poland.
Robert ZdanowskiDepartment of Regenerative Medicine, Military Institute of Hygiene and Epidemiology, Warsaw, Poland.
Marek BrytanDepartment of Pharmacology and Toxicology, Military Institute of Hygiene and Epidemiology, Warsaw, Poland.
Grzegorz KadeDepartment of Internal Diseases, Nephrology and Dialysis, Military Institute of Medicine, Warsaw, Poland.
Zbigniew NowakDepartment of Internal Diseases, Nephrology and Dialysis, Military Institute of Medicine, Warsaw, Poland.
Janusz PateraDepartment of Pathology, Military Institute of Medicine, Warsaw, Poland.
Przemysław DyrlaDepartment of Gastroenterology, Military Institute of Medicine, Warsaw, Poland.
Jerzy GilDepartment of Gastroenterology, Military Institute of Medicine, Warsaw, Poland.
Zofia WańkowiczDepartment of Internal Diseases, Nephrology and Dialysis, Military Institute of Medicine, Warsaw, Poland.
Wojskowy Instytut Medycyny Lotniczej · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundShort-term administration of Galactosamine to experimental animals causes liver damage and acute liver failure (ALF), as well as acute renal failure in some cases. The aim of our study was to describe kidney disorders that developed in the course of galactosamine-induced liver failure. MATERIAL AND

methodsSprague-Dawley rats were randomly divided into 2 groups: a study group administered galactosamine intraperitoneally and a control group administered saline.

resultsAll the animals in the study group developed liver damage and failure within 48 h, with significant increase of alanine (p<0.001), aspartate aminotransferases (p<0.0001), bilirubin (p<0.004), and ammonia (p<0.005) and decrease of albumin (p<0.001) concentrations. Acute renal failure was observed in all test animals, with a significant increase in creatinine (p<0.001) and urea (p<0.001) concentrations and a decrease in creatinine clearance (p<0.0012). Moreover, osmotic clearance (p<0.001), daily natriuresis (p<0.003), and fractional sodium excretion (p<0.016) decreased significantly in this group of animals. The ratio of urine osmolality to serum osmolality did not change. Histopathology of the liver revealed massive necrosis of hepatocytes, whereas renal histopathology showed no changes.

conclusionsAcute renal failure that developed in the course of galactosamine-induced ALF was of a functional nature, with the kidneys retaining the ability to concentrate urine and retain sodium, and there were no renal changes in the histopathological examination. It seems that the experimental model of ALF induced by galactosamine can be viewed as a model of hepatorenal syndrome that occurs in the course of acute damage and liver failure.

Indexed as

Disease Models, AnimalAcute Kidney InjuryAlanine TransaminaseAlbuminsAmmoniaAnimalsAspartate AminotransferasesBilirubinCreatinineGalactosamineHepatocytesInjections, IntraperitonealLiver FailureOsmolar ConcentrationProteinuriaRatsAlanine TransaminaseAlbuminsAmmoniaAspartate AminotransferasesBilirubinCreatinineGalactosamineUrea

Identifiers

PMID26009004
PMCPMC4451715
OpenAlexW1931349869

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.